At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
|Articles|May 9, 2012
Jawboning by HHS Doesn't Scare Insurers
Advertisement
The Department of Health and Human Services isn’t that much of a bully, it turns out.
Health insurers flagged by the department for “unreasonable” premium hikes are refusing to back down in the first year of HHS’s new rate review authority.
Read the full story:
Source: Politico
The health reform law gave HHS the power to scrutinize “unreasonable” rate hikes in states that didn’t have robust review programs. But “scrutiny” doesn’t give the department power to actually block the rates from going into effect.
Advertisement
Related to this article
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.
Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.
Advertisement
Advertisement
Trending on AJMC
1
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
2
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
3
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
4
CHEST: The Face of Lung Cancer Has Changed, but Screening, Care Have Gaps
5